Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
OKLAHOMA CITY, Feb. 13, 2018 -- Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces completion of first batch in new state-of-the-art 1000L microbial facility.
“The Cytovance team has successfully completed our first run in our new state-of-the-art microbial facility,” said Michael O Mara, SVP of Manufacturing. "It was a great moment for the late phase client and the entire Cytovance team.” The 30,000-square foot facility houses a 14L fermentor, a 300L SUF (Q3 2018) and a 1000L working volume Dakota Fermentor. Also, housed in this facility is a GEA Homogenizer, Alfa Laval MBPX810 Disc Stack Centrifuge and a P-12 Powerfuge. The purification suite features 2 x 5000L imPULSE Mixers for refolding, Chromatography skid, a Millipore TFF Skid, 1” & 10mm AKTA Process and AKTA Ready, all with gradient function.
“The upstream material is processed by the downstream purification equipment,” said Stephanie Wickham, Director of Manufacturing Sciences. “Our 2x5000L imPULSE Mixers give us exactly what we need for our refold processes. Highly efficient mixing with very low shear rates, is critical in the protein refolding process and with a large turndown ratio, we have the ability to process at a variety of refold volumes.”
By reallocating resources, hiring external contractors and improving efficiencies gained in equipment commissioned, Cytovance was able to have building 3500 up and running 4 months prior to the “go live” date. This was a huge success not only for Cytovance but our client as well who needed the data gained for an FDA inspection.
About Cytovance Biologics
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its Oklahoma City state-of-the-art facilities.
Media Contact: Cheryl Tuck, [email protected]
